Allergan (AGN +1.3%) saw a bounce in its Botox migraine share last month, according to Wells Fargo. The firm says research data for February shows it with an 8.8% market share among sample neurologists, up from 5.3% in January and 8.4% in December. Wells estimates U.S. sales are close to $300M annually, tracking ahead of estimates. The firm maintains its Outperform rating on the stock.